Sinapsos Podcast | Oncology

By Sinapsos Podcast

Zero Fluff. Pure Insight.

Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no fi

... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about Sinapsos Podcast | Oncology:

How many episodes does Sinapsos Podcast | Oncology have?

The podcast currently has 65 episodes available.

Sinapsos Podcast | Oncology episodes:

January 06, 2026E1 - Neutropenia in Esophageal Cancer Treatment
E1 | 12 min | Latest | https://www.mdpi.com/2072-6694/18/1/112
Podcast based on: Sakai, M.; Nakazawa, N.; Kuriyama, K.; Okada, T.; Shiraishi, T.; Kumakura, Y.; Kimura, A.; Sano, A.; Yokobori, T.; Shirabe, K.; Saeki, H. Therapy-Induced Neutropenia and Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Who Underwent Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil. Cancers 2025, 18, 112. https://doi.org/10.3390/cancers18010112
Type: Article| Publication date: 29 December 2025

Summary: Therapy-induced neutropenia is a common complication that occurs during definitive chemoradiotherapy for locally advanced esophageal cancer, but its prognostic significance is still unclear. In this study, we found that patients who developed severe neutropenia (Grade 3–4) during treatment had significantly worse overall survival compared to those with mild or no neutropenia. Notably, severe neutropenia was linked to greater reductions in lymphocyte counts at the time of cancer recurrence, indicating an impaired ability of the immune system to recover. These findings suggest that therapy-induced neutropenia not only reflects treatment toxicity but may also predict insufficient lymphocyte recovery and compromised antitumor immunity. Our results emphasize the need for further prospective studies to better understand the clinical and immunological consequences of myelosuppression in multimodal esophageal cancer therapy.

Keywords: esophageal cancer; chemoradiotherapy; overall survival; neutropenia

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
...more
12min
January 06, 2026E2 - Neutropenia in Esophageal Cancer Therapy
E2 | 11 min | Latest | https://www.mdpi.com/2072-6694/18/1/112
Podcast based on: Sakai, M.; Nakazawa, N.; Kuriyama, K.; Okada, T.; Shiraishi, T.; Kumakura, Y.; Kimura, A.; Sano, A.; Yokobori, T.; Shirabe, K.; Saeki, H. Therapy-Induced Neutropenia and Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Who Underwent Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil. Cancers 2025, 18, 112. https://doi.org/10.3390/cancers18010112
Type: Article| Publication date: 29 December 2025

Summary: Therapy-induced neutropenia is a common complication that occurs during definitive chemoradiotherapy for locally advanced esophageal cancer, but its prognostic significance is still unclear. In this study, we found that patients who developed severe neutropenia (Grade 3–4) during treatment had significantly worse overall survival compared to those with mild or no neutropenia. Notably, severe neutropenia was linked to greater reductions in lymphocyte counts at the time of cancer recurrence, indicating an impaired ability of the immune system to recover. These findings suggest that therapy-induced neutropenia not only reflects treatment toxicity but may also predict insufficient lymphocyte recovery and compromised antitumor immunity. Our results emphasize the need for further prospective studies to better understand the clinical and immunological consequences of myelosuppression in multimodal esophageal cancer therapy.

Keywords: esophageal cancer; chemoradiotherapy; overall survival; neutropenia

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
...more
11min
January 06, 2026 E2 - Neutropenia in Esophageal Cancer Therapy
WAIT 3
...more
11min
January 06, 2026 E2 - Neutropenia in Esophageal Cancer Therapy
WAIT 3
...more
11min
January 06, 2026 E2 - Neutropenia in Esophageal Cancer Therapy
...more
11min
January 06, 2026 E2 - Neutropenia in Esophageal Cancer Therapy
"C:\Podcast\PAD_Automations\copy_description.py"
...more
11min
January 06, 2026 E2 - Neutropenia in Esophageal Cancer Therapy
1. Role & Context Persona: Senior Python Developer. Project Scope: Documentation Automation & Markdown Management. 2. The Mission Analyze all Python (.py) files within the current directory and generate structured descriptions for each, appending them to the existing Scripts Description.md file. The goal is to create a comprehensive "Source of Truth" for the repository's functionality using the established Markdown format. 3. Expected Behavior File Discovery: Scan the root directory for all .py files. Logic Extraction: * Read the source code of each script. Identify the primary objective (e.g., file I/O, API interaction, data processing). Extract key features (libraries used, specific Excel operations, clipboard actions, etc.). Formatting: For each new script, generate a section that includes: A numbered header (e.g., ##### 3. script_name.py). A brief "purpose" line in parentheses. A list of functional "✅" bullet points. Content Alignment: Mirror the style of update_lengths.py and copy_description.py, focusing on technical actions (e.g., "Uses [library]", "Handles [error]", "Saves [file]"). Appending: Write the new descriptions to the end of Scripts Description.md without overwriting or refactoring the existing content. 4. Technical Constraints Language: Python analysis logic. Preservation: Do not modify any .py files. Only modify Scripts Description.md. Style Match: Ensure the indentation, spacing ( ), and emoji usage match the reference document exactly. 5. Verification Steps Terminal Command: Run cat "Scripts Description.md" to verify the content has been appended. Validation: Ensure the number of headers in the Markdown file matches the total number of Python scripts in the directory. Success Artifact: A complete Scripts Description.md file where every script has a "Mission-ready" summary. 6. Mission Summary (Antigravity Task List) [ ] Scan directory for all .py files not already documented in Scripts Description.md. [ ] Analyze script logic and external library dependencies. [ ] Draft a concise summary and functional checklist for each script. [ ] Format the draft to match the provided Markdown template (Header, subtitle, and ✅ points). [ ] Append the new descriptions to Scripts Description.md. [ ] Verify formatting consistency across the entire document.
...more
11min
January 22, 2025Treatment Patterns in Lung Cancer Brain Metastasis
E18 | 14 min | Latest | Publication Source
Podcast based on: Mobley JM, Phillips KI, Chen Q, Reusch E, Reddy N, Magsam JB, McLouth LE, Huang B, Villano JL. Outcomes of Brain Metastasis from Lung Cancer. Cancers. 2025; 17(2):256. https://doi.org/10.3390/cancers17020256
Type: Article | Publication date: Jan 14, 2025

Summary: This study investigated treatment patterns in 284 Kentucky lung cancer patients with brain metastases, focusing on the 21.8% who received no treatment. Researchers analysed factors influencing treatment decisions, including social history (tobacco use proved statistically significant), disease burden, and access to oncology care. The high incidence of lung cancer in Kentucky provided a relevant context for the study. Findings highlighted potential barriers to care and suggested strategies for improving treatment access and patient outcomes, acknowledging limitations of a retrospective, single-institution study.

Keywords: lung cancer; brain metastasis; non-treatment; palliative care

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
...more
15min
January 21, 2025Recent Advances in Small-Cell Lung Cancer Therapeutics
E17 | 19 min | Latest | Publication Source
Podcast based on: Das S, Samaddar S. Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics. Cancers. 2025; 17(2):255. https://doi.org/10.3390/cancers17020255
Type: Review | Publication date: Jan 14, 2025

Summary: This research review comprehensively examines small-cell lung cancer (SCLC), a highly aggressive and often fatal lung cancer. It details SCLC's cellular origins, neuroendocrine characteristics, and diverse subtypes driven by distinct transcriptional regulators. The review also explores the mechanisms of chemoresistance, focusing on DNA damage response pathways, cancer stem cells, and epigenetic reprogramming. Finally, it summarises recent advancements and ongoing clinical trials investigating novel targeted therapies, including immune checkpoint inhibitors, topoisomerase inhibitors, and agents targeting DLL3, HDACs, and PARP.

Keywords: small-cell lung cancer; molecular subtypes; chemotherapy; resistance

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
...more
20min
January 20, 2025Tumor Dormancy: Clinical Opportunities and Challenges
E16 | 16 min | Latest | Publication Source
Podcast based on: Boydell E, Borgeaud M, Tsantoulis P. Dormant Tumor Cells: Current Opportunities and Challenges in Clinical Practice. Onco. 2025; 5(1):3. https://doi.org/10.3390/onco5010003
Type: Review | Publication date: Jan 10, 2025

Summary: This research review examines dormant tumour cells, cells that remain inactive after cancer treatment, potentially causing relapse. It explores the molecular mechanisms underlying dormancy, the role of the immune system and microenvironment, and the challenges in detecting these cells clinically. The review also discusses potential therapeutic strategies, including maintaining dormancy, eradicating dormant cells, and targeting the tumour's niche, highlighting the complexities and limitations of current approaches. Finally, it emphasises the need for clinically meaningful endpoints in future trials focusing on dormant tumour cells.

Keywords: disseminated tumor cells; dormancy; minimal residual disease; breast cancer

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
...more
17min

FAQs about Sinapsos Podcast | Oncology:

How many episodes does Sinapsos Podcast | Oncology have?

The podcast currently has 65 episodes available.